Clinical trials: Systolic Murmurs
Uncontrolled Hypertension
A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension
The purpose of this clinical trial is to measure the safety and efficacy of RTN-001 in adult participants with uncontrolled hypertension versus placebo.
- Trial name
- NCT07142356
- Testing
- RTN-001
- Where
- 34 sites in United States
- Volunteers
- 280 people
- Sponsor
- Retension Pharmaceuticals. Inc.
Chronic Heart Failure
Efficacy and Safety of Human Neuregulin-1 to Treat Stable Chronic Heart Failure
The mortality of chronic heart failure patients remains high. Recombinant human Neuregulin-1 (rhNRG-1, also called Neucardin) is a 61 amino acid peptide that acts directly on damaged heart muscle cells to restore their structure…
- Trial name
- ZS-01-210 (NCT01251406)
- Testing
- rhNRG-1 Dose 1, rhNRG-1 Dose 2
- Where
- 13 sites in United States
- Volunteers
- 67 people
- Sponsor
- Zensun Sci. & Tech. Co., Ltd.
Hypertension
A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients
Evaluate the diastolic blood pressure lowering effect of combination of aliskiren 300 mg and HCTZ (12.5 mg and 25 mg) in hypertensive patients who do not show sufficient blood pressure response to aliskiren 300 mg.
- Trial name
- NCT00386139
- Testing
- Aliskiren/HCTZ
- Where
- 2 sites in United States, Germany
- Volunteers
- 881 people
- Sponsor
- Novartis
Hypertension
Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension
The purpose of this trial is to evaluate the safety and efficacy of combination therapy of aliskiren/hydrochlorothiazide (HCTZ) 150/25 mg and 300/25 mg compared with HCTZ 25 mg in patients with hypertension who do not show…
- Trial name
- NCT00387517
- Testing
- Aliskiren/HCTZ
- Where
- 2 sites in United States, Germany
- Volunteers
- 726 people
- Sponsor
- Novartis
Hypertension
Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension
The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of Black stage II hypertensive patients (MSSBP ≥ 160 mmHg).
- Trial name
- NCT00353912
- Testing
- valsartan + amlodipine
- Where
- United States
- Volunteers
- 571 people
- Sponsor
- Novartis
Heart Failure, Congestive, Heart Decompensation
Evaluation of the Effects of Carperitide in Patients With Congestive Heart Failure
The study will evaluate the safety and efficacy of intravenous infusion of carperitide using pressure measurements inside the heart and great vessels and measuring carperitide concentration in the blood.
- Conditions
- Heart Failure, Congestive, Heart Decompensation, Left Ventricular Failure, Myocardiopathies
- Trial name
- NCT00259038
- Testing
- Carperitide
- Where
- 34 sites in United States, Canada
- Volunteers
- 162 people
- Sponsor
- Daiichi Sankyo
Heart Rate, Blood Pressure
Safety of Phenylephrine Hydrochloride, Acetaminophen, Dimethindene Maleate Compared to Phenylephrine Hydrochloride Alone in Healthy Volunteers
This study will evaluate the safety of phenylephrine hydrochloride 10 mg + acetaminophen 500 mg + dimethindene maleate 1 mg compared to phenylephrine hydrocloride 10 mg alone in healthy volunteers.
- Conditions
- Heart Rate, Blood Pressure, Arrhythmias
- Trial name
- NCT01026961
- Testing
- Phenylephrine HCL, Phenylephrine HCL/Acetaminophen/Dimethindene Maleate
- Where
- Brazil
- Sponsor
- Novartis
Heart Failure
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
In addition to the blood pressure lowering effects of aliskiren, it may have beneficial effects on blocking the so called RAAS (renin-angiotensin-aldosterone system) at the tissue level.
- Trial name
- ESCAPE-SHF (NCT00923156)
- Testing
- aliskiren, ramipril
- Where
- 16 sites in Germany, Poland and 1 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals